Morgan Stanley Seelos Therapeutics, Inc. Transaction History

Morgan Stanley

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$0.16 - $1.64 $18,641 - $191,078	116,511 Added 30.59%	497,380 $89,000
Q2 2023 Aug 14, 2023	BUY	$0.66 - $1.22 $20,770 - $38,394	31,471 Added 9.01%	380,869 $457,000
Q1 2023 May 15, 2023	SELL	$0.59 - $1.04 $1,142 - $2,014	-1,937 Reduced 0.55%	349,398 $241,000
Q4 2022 Feb 14, 2023	BUY	$0.66 - $1.34 $19,856 - $40,315	30,086 Added 9.37%	351,335 $238,000
Q3 2022 Nov 14, 2022	SELL	$0.65 - $1.41 $37,902 - $82,218	-58,311 Reduced 15.36%	321,249 $331,000

Q2 2022 Oct 27, 2022	BUY	$0.51 - $0.93 $5,499 - $10,028	10,783 Added 2.92%	379,560 $258,000
Q2 2022 Aug 15, 2022	BUY	$0.51 - $0.93 $5,499 - $10,028	10,783 Added 2.92%	379,560 $258,000
Q1 2022 Oct 27, 2022	SELL	$0.84 - $1.71 $9,057 - $18,438	-10,783 Reduced 2.84%	368,777 $309,000
Q1 2022 May 13, 2022	BUY	$0.84 - $1.71 $23,672 - $48,191	28,182 Added 8.27%	368,777 $309,000
Q4 2021 Feb 14, 2022	BUY	$1.59 - $2.38 $327,194 - $489,763	205,783 Added 152.64%	340,595 $555,000
Q3 2021 Nov 15, 2021	BUY	$1.69 - $2.89 $227,832 - $389,606	134,812 New	134,812 $325,000

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $59.7M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.